Home » Stocks » CLBS

Caladrius Biosciences, Inc. (CLBS)

Stock Price: $2.02 USD -0.11 (-4.95%)
Updated Feb 25, 2021 2:21 PM EST - Market open
Market Cap 122.58M
Revenue (ttm) n/a
Net Income (ttm) -7.68M
Shares Out 18.60M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $2.02
Previous Close $2.12
Change ($) -0.11
Change (%) -4.95%
Day's Open 2.08
Day's Range 1.93 - 2.10
Day's Volume 2,931,472
52-Week Range 1.05 - 4.89

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

BASKING RIDGE, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

GlobeNewsWire - 1 week ago

BASKING RIDGE, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

GlobeNewsWire - 1 week ago

BASKING RIDGE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

GlobeNewsWire - 4 weeks ago

BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

GlobeNewsWire - 1 month ago

BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

GlobeNewsWire - 1 month ago

BASKING RIDGE, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

InvestorPlace - 1 month ago

Caladrius Biosciences is focused on treating coronary microvascular dysfunction. The condition is most common among women, especially after menopause.

GlobeNewsWire - 1 month ago

Initiation of the Phase 2b FREEDOM trial represents the next step in development of CLBS16 as a potential breakthrough treatment for the millions of sufferers of CMD in the U.S., most of whom ...

GlobeNewsWire - 1 month ago

BASKING RIDGE, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

GuruFocus - 1 month ago

The short term investor may want to consider this trio of companies

Other stocks mentioned: JT, RMED
GlobeNewsWire - 2 months ago

BASKING RIDGE, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

GlobeNewsWire - 3 months ago

The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer

GlobeNewsWire - 3 months ago

BASKING RIDGE, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

Seeking Alpha - 3 months ago

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

BASKING RIDGE, N.J. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the d...

GlobeNewsWire - 3 months ago

BASKING RIDGE, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

GlobeNewsWire - 3 months ago

BASKING RIDGE, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

GlobeNewsWire - 4 months ago

BASKING RIDGE, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

GlobeNewsWire - 4 months ago

Patient screening begins immediately at NYU Langone Health

GlobeNewsWire - 4 months ago

BASKING RIDGE, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

GlobeNewsWire - 4 months ago

BASKING RIDGE, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de...

GlobeNewsWire - 5 months ago

BASKING RIDGE, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...

GlobeNewsWire - 5 months ago

BASKING RIDGE, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...

Seeking Alpha - 6 months ago

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

BASKING RIDGE, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the ...

GlobeNewsWire - 6 months ago

BASKING RIDGE, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the ...

GlobeNewsWire - 6 months ago

BASKING RIDGE, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the ...

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Caladrius Biosciences (CLBS) stock based on the movements in the options market lately.

GlobeNewsWire - 8 months ago

BASKING RIDGE, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the d...

GlobeNewsWire - 9 months ago

Single administration of CLBS16 durably improves heart function and symptoms in patients with coronary microvascular dysfunction Single administration of CLBS16 durably improves heart function...

Seeking Alpha - 9 months ago

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

BASKING RIDGE, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...

GlobeNewsWire - 10 months ago

BASKING RIDGE, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...

GlobeNewsWire - 10 months ago

FDA authorizes new IND for the study of CLBS119 in COVID-19 patients who experienced respiratory failure FDA authorizes new IND for the study of CLBS119 in COVID-19 patients who experienced re...

GlobeNewsWire - 10 months ago

BASKING RIDGE, N.J., April 22, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), today announced that it has finalized an agreement to sell ...

Seeking Alpha - 11 months ago

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events

Seeking Alpha - 1 year ago

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for July 25th

Other stocks mentioned: FNV, GNTX, POL
Seeking Alpha - 1 year ago

Caladrius Biosciences, Inc.'s (CLBS) CEO David Mazzo on Q1 2019 Earnings Conference Call Transcript

Seeking Alpha - 1 year ago

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2018 Earnings Conference Call Transcript

About CLBS

Caladrius Biosciences, a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 for the treatment of critical limb ischemia; CLBS16, which is in Phase II clinical trial for the treatment of coronary microvascular dysfunction; CLBS14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. The company was formerly known a... [Read more...]

Industry
Biotechnology
Founded
1980
CEO
David Mazzo
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
CLBS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for CLBS stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 346.65% from the latest price.

Price Target
$9.00
(346.65% upside)
Analyst Consensus: Buy